Clinical Trials

CNSDermatologicGastrointestinalGenitourinaryLymphoidSarcoma

23 enrolled

Carcinoma, Renal Cell, Digestive System Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Adenocarcinoma, Clear Cell, Rhabdoid Tumor

NCT04150497 2025-09-09

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Phase 1/2 Recruiting

52 enrolled

Burkitt Lymphoma, Recurrence

NCT05607420 2025-08-24

NatHaLi-01

Phase 1/2 Recruiting

80 enrolled

Phase 2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT01361711 2025-05-23

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

53 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06705608 2024-11-26

MS; FTY720

Completed

4,000 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Multiple Sclerosis, Skin Neoplasms, Multiple Sclerosis, Relapsing-Remitting

NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

15 enrolled

Leukemia, Prolymphocytic, T-Cell

NCT02626715 2024-07-16

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

MyeloidOther hematologic neoplasm

21 enrolled 24 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Phase 1/2 Active not recruiting

14 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Neutropenia, Severe Congenital, Autosomal Recessive 3, Bone Marrow Failure Disorders, Shwachman-Diamond Syndrome, Primary Immunodeficiency Diseases, Acquired Immunodeficiency Syndrome, Anemia, Aplastic, Anemia, Sickle Cell, Hemoglobinopathies, Histiocytosis, Langerhans-Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Histiocytosis, Anemia, Diamond-Blackfan, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Macrophage Activation Syndrome

NCT03821610 2024-05-16

ALL-RIC

Phase 2 Active not recruiting

242 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02385110 2024-01-17

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

MyeloidOther hematologic neoplasm

18 enrolled 10 charts

Leukemia, Lymphohistiocytosis, Hemophagocytic

NCT00047060 2023-11-14

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

5 enrolled 18 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00074282 2023-06-29

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

102 enrolled 11 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01013961 2023-06-28

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Phase 2 Terminated

31 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00006390 2023-06-22

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01256398 2023-04-04

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

66 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00199030 2023-03-20

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

8 enrolled

Lymphoma, Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01030900 2022-10-06

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

50 enrolled 13 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Phase 1 Unknown

71 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT01982175 2022-06-21

CLL004

Phase 2 Suspended

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

302 enrolled 11 charts

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00345345 2022-05-03

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Other hematologic neoplasm

29 enrolled 17 charts

Leukemia, Neutropenia, Leukemia, Large Granular Lymphocytic

NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

DermatologicLymphoidOther hematologic neoplasm

11 enrolled 16 charts

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT00951457 2022-03-03

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00069238 2022-02-24

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

31 enrolled 12 charts

Lymphoma, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01186640 2022-01-05

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

16 enrolled

Leukemia, Prolymphocytic, T-Cell

NCT02497404 2021-09-22

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

MyeloidOther hematologic neoplasm

40 enrolled 21 charts

Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes

NCT02059239 2021-02-21

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

34 enrolled 22 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00858117 2020-11-06

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

30 enrolled 11 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00536978 2020-09-24

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

22 enrolled 5 charts

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00983528 2020-08-12

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1/2 Terminated

6 enrolled 6 charts

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01269385 2020-06-23

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

22 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00578292 2020-05-01

THALLO

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

NCT00566696 2020-04-14

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasm

73 enrolled 16 charts

Hemoglobinuria, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT00562328 2020-04-08

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

33 enrolled 12 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01596699 2020-02-26

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Phase 2 Terminated

16 enrolled 11 charts

Bone Marrow Failure Disorders, Metabolic Diseases

NCT00553098 2020-02-17

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

29 enrolled 19 charts

Immunologic Deficiency Syndromes

NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

60 enrolled 10 charts

Congenital Abnormalities, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00368355 2020-01-21

MOHEL

LymphoidMyeloidOther hematologic neoplasm

46 enrolled 12 charts

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00048412 2020-01-18

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

LymphoidOther hematologic neoplasmPlasma cell

40 enrolled

Leukemia, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias

NCT00057005 2020-01-18

ADVL

Other hematologic neoplasm

6 enrolled

Leukemia

NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 1/2 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01392079 2019-10-24

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

135 enrolled

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00997386 2019-09-09

ALBUM